Kim Steegen to Anti-HIV Agents
This is a "connection" page, showing publications Kim Steegen has written about Anti-HIV Agents.
Connection Strength
3,058
-
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
Score: 0,445
-
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Pediatr Infect Dis J. 2022 10 01; 41(10):827-834.
Score: 0,428
-
Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021 09 15; 76(10):2659-2665.
Score: 0,404
-
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. J Int AIDS Soc. 2021 05; 24(5):e25706.
Score: 0,394
-
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.
Score: 0,243
-
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
Score: 0,126
-
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20; 16(9).
Score: 0,125
-
Recommendations on data sharing in HIV drug resistance research. PLoS Med. 2023 Sep; 20(9):e1004293.
Score: 0,116
-
Resistance is common in paediatric patients failing ART in South Africa. J Antimicrob Chemother. 2023 05 03; 78(5):1160-1167.
Score: 0,113
-
High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine (Baltimore). 2020 Sep 11; 99(37):e21661.
Score: 0,094
-
PhyloPi: An affordable, purpose built phylogenetic pipeline for the HIV drug resistance testing facility. PLoS One. 2019; 14(3):e0213241.
Score: 0,085
-
Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):73-78.
Score: 0,084
-
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018 11; 5(11):e638-e646.
Score: 0,082
-
Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
Score: 0,072
-
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016 09; 21(9):1131-7.
Score: 0,070
-
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016 10; 71(10):2918-27.
Score: 0,070
-
Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009 May; 53(5):2185-8.
Score: 0,042
-
A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006 May; 133(2):137-45.
Score: 0,034
-
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
Score: 0,016
-
HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One. 2012; 7(4):e34708.
Score: 0,013